Ginkgo Bioworks Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 2026 revenue was $28 million, down 6% compared to the third quarter of 2025; revenue for the nine months of 2026 was $67 million, down 37% compared to the same period last year.
- Excluding $7.5 million of non-cash revenue in the first nine months of 2025 related to the mutual termination of the BiomEdit agreement, revenue for the first nine months of 2026 was down approximately 32% from the prior year period.
- Third-quarter revenue was higher than last quarter primarily because a modified long-term contract led to a cumulative catch-up and earlier revenue recognition.
- Q3 2026 R&D expense decreased 48% to $27 million from $51 million, and G&A expense decreased 32% to $9 million from $14 million, primarily due to restructuring efforts substantially completed by the end of 2025.
- Net loss from continuing operations was $41 million, a 44% improvement from $73 million in the prior year period; adjusted EBITDA was negative $22 million, a 58% improvement from negative $53 million.
- Cash burn was $27 million in Q3 2026 compared to $28 million in Q3 2025, and was $120 million for the first nine months of 2026 compared to $124 million in the same period last year.
- Adjusted EBITDA included approximately $14 million of carrying cost for excess leased space in both periods.
- Ginkgo ended the quarter with $285 million in cash equivalents and marketable securities, no bank debt, and $86 million of restricted cash equivalents and marketable securities.
- Ginkgo raised an additional net $7 million through its at-the-market equity program during the third quarter; those proceeds are excluded from cash burn.
- Ginkgo added 20 new biopharma or biotech customer logos in the quarter and reported 22 customers for the Cloud Lab business.
- Novo Nordisk selected Ginkgo to build an autonomous lab at its new R&D site in Waltham, marking Ginkgo's first announced autonomous lab hardware contract with a big pharma company.
- MIT, Caltech, Maryland, and Northwestern selected Ginkgo for autonomous lab projects; Caltech, Maryland, and Northwestern are part of an NSF program with close to $50 million flowing through it.
- ARPA-H selected Ginkgo as a subcontractor on an award of up to $17.5 million for robotics supporting manufacturing of genetic medicines.
- Ginkgo is building a 97 RAC system for Pacific Northwest National Labs and is developing and validating instruments and subsystems for the installation.
- Ginkgo launched its Antibody Developability Consortium with AbbVie, argenx, Lundbeck, and Takeda as founding members, and announced a partnership with Lilly TuneLab to make Ginkgo Datapoints services available to members.
- Ginkgo said its Nebula Cloud Lab has 105 RACs, runs 24/7, supports more than 100 protocols and more than 30 unique protocols in a single day, and has more than 160 lab devices.
- Management said Q3 improvements in net loss and adjusted EBITDA reflected efforts to reduce spending while continuing investment in research and development around autonomous labs, AI, and laboratory robotics.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
manager of communications and ownership. I am joined by Jason Kelly, our Co-founder and CEO, and Steve Cullen, our CFO. Thanks as always for joining us. We are looking forward to updating you on our progress. As a reminder, during the presentation today, we will be making forward-looking statements which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10-K. Today, in addition to updating you on the quarter's results, we are going to show how Ginkgo is now two businesses built on one autonomous lab platform at a moment when the U.S. government is starting to treat autonomous labs as national infrastructure. We will share how our autonomous labs business is growing, including our first autonomous lab sale to a pharma company, Novo, alongside new government wins with ARPA-H and the NSF.
We will also share how our Cloud Lab business is growing with new pharma logos, including 22 customers this quarter, and with AI data generation for frontier labs. As usual, we will end with a Q&A session, and I will take questions from analysts, investors, and the public. You can submit those questions to us in advance via X, #GinkgoResults, or email investors@ginkgobioworks.com. All right, over to you, Jason.
Thanks, Daniel. As I always say, our mission here at Ginkgo is to make biology easier to engineer. Over the last few years, we have been going through a transformation with this focus on autonomous labs, and that was really our goal in 2026. I will say I think that succeeded very well. This quarter is really good evidence of that. We have been focusing our efforts on moving more and more of our internal lab work onto autonomous labs. That continues, and improving the product. A real breakthrough in the last quarter in terms of external customers adopting our systems. We will be happy to talk about some of the new customers we have for autonomous labs, both in universities and the biopharma sector, and we have been expanding the services that we are offering on top of our big system in Boston here in Nebula. Really happy about this. I think we made the right choice in betting on this technology.
You are going to hear more from me on that in the strategic section. Our financials have been going in the right direction. We made a big push to cut back on spending while still making major investments in research and development around autonomous labs, AI, and robotics in the laboratory, and that has also paid off. You can see our year-over-year change here, pretty substantial improvements in net loss from continuing operations as well as our total adjusted EBITDA. This is what we were aiming to achieve, and really congrats to the team on pulling this off. It is hard to do these two things at once, cost-cutting and being really the technology leader in an emerging tech area, especially one next to AI.
All right, last thing I'll mention, we have still quite a nice cash cushion. This is, again, thanks to those cost-cutting efforts, $285 million in cash and cash equivalents, with no bank debt, and another $86 million on top of that that we keep as restricted cash for some of our government projects and leases. Overall, I like our position from a cash position. I like where we are with cash spending, and as you're going to hear from me in the strategic section, I think we're doing a nice job externally selling and improving really a new category of product in autonomous labs. Back to me in a moment, but I'm going to hand it to Steve to a little more depth on the financials.
Thanks, Jason. Before I walk through our financials, I want to remind everyone that our biosecurity results are classified as discontinued operations within our financial statements, where we have and will retrospectively recast all prior periods presented to conform to this presentation. All the financial information I will cover today relates exclusively to continuing operations, where we operate as a single segment. With that, I will now discuss our Q3 results. As Jason mentioned, revenue was $28 million in the third quarter of 2026, down 6% compared to the third quarter of 2025. For the nine months of 2026, revenue was $67 million, down 37% compared to the same period last year. As previously disclosed, revenue in the first nine months of 2025 included $7.5 million of non-cash revenue relating to the mutual termination of the BiomEdit agreement.
Excluding this, revenue for the first nine months of 2026 was down approximately 32% from the prior year period. As noted in our release, revenue in the third quarter was higher than last quarter, and this was primarily from a cumulative catch-up on one of our larger long-term contracts, which was modified to realign the work plan, resulting in us recognizing some revenue soon. It is important to note that our net loss includes a number of non-cash and other non-recurring items, as detailed more fully in our financial statements. Because of these non-cash and non-recurring items, we believe adjusted EBITDA is a more indicative measure of our profitability. A full reconciliation between adjusted EBITDA and GAAP net loss from continuing operations can be found in the appendix. In addition, in discussing our R&D and G&A expenses, we exclude stock-based compensation and other separately captioned items.
In the third quarter of 2026, R&D expense decreased 48% from $51 million in the third quarter of 2025 to $27 million in the third quarter of 2026. G&A expense decreased 32% from $14 million in the third quarter of 2025 to $9 million in the third quarter of 2026. These decreases were primarily driven by our restructuring efforts, which were substantially completed by the end of 2025. Moving further down the page, net loss from continuing operations was $41 million in the third quarter of 2026, compared to a loss of $73 million in the prior year period, a 44% improvement. You will note that adjusted EBITDA in the third quarter of 2026 was negative $22 million, compared to negative $53 million in the third quarter of 2025, a 58% improvement.
It is important to note that adjusted EBITDA includes the carrying cost of excess leased space, which you can see was approximately $14 million in both periods. This cash operating cost represents the base rent and other charges relating to unused leased space, net of subleasing income, that is not driving revenue right now and can potentially be mitigated through subleasing. Finally, cash burn in the third quarter of 2026 was $27 million, compared to $28 million in the third quarter of 2025. For the nine months of 2026, cash burn was $120 million, down from $124 million in the same period last year, a 4% decrease. As previously reported, we paid Google Cloud $14 million earlier this year as part of the favorable restructuring of that contract late last year.
Excluding this payment, cash burn reflects a significant decrease in the first nine months of 2026 compared to the first nine months of 2025, which was directly a result from the restructuring, partially offset by the investments we are making. During the third quarter, we raised an additional net $7 million through our at-the-market equity program. Consistent with our methodology, these related proceeds are excluded from cash burn for all periods presented. As previously reported, cash burn excludes the restrictions we made last quarter to secure a surety bond on our PNNL contract. We ended the quarter with $285 million in cash equivalents, and marketable securities, and no bank debt, plus $86 million of restricted cash equivalents, and marketable securities for customers and operating activities. Now, turning to guidance. As we discussed earlier this year, 2026 is about continuing to be cost-efficient while investing in our AI robotics and software to bring autonomous labs to our bioscience customers, including the build-out of our Frontier Autonomous Lab in Boston.
For these reasons, we believe cash burn best reflects our continuing services and tools and further investments in autonomous labs. In terms of the outlook for the full year, we are reaffirming our overall cash burn guidance for 2026, totaling $125 million-$150 million. This range reflects a firm balance amongst cost efficiency, continuing services and tools, and further investments we are making. In conclusion, we are pleased with the continued improvements in cash burn efficiency and our business pursuits for 2026. With that, I will hand it back over to you, Jason.
Thanks, Steve. Our mission here at Ginkgo is to make biology easier to engineer. As I mentioned, we have been doing that by expanding our technology and autonomous labs and bringing those to market. I will say they are currently having a moment. Big push on the government side, a lot more attention from private sector biopharma, and as I will talk about it, even frontier AI labs are getting excited about the potential of robotic laboratories. We sell those in two different ways, both hardware, we will install an autonomous lab for you, or you can leverage our autonomous lab as a cloud. Those are going to be my two sections. You are going to hear about sort of the blue chip early adopters we are seeing on selling our systems, as well as the growth in the services.
All right, it is a moment, I do want to just highlight a few of the good things that have been moving in our favor over the last quarter. I just, a few weeks ago, was at President Trump's Golden Age of Science Summit. This was to announce a report out of the Office of Science and Technology Policy. I have mentioned this before, but there is a little clip in there from the report about accelerating autonomous experimentation. We have seen real money coming behind this, $400 million going to the National Science Foundation to invest in this. The Genesis Mission, which is partially what funded our big project at the Pacific Northwest National Lab. I think you will continue to see more of this coming from the White House as we expand AI in science in the U.S.
Importantly, our bigger customer base ultimately, I think, is the biopharma companies. Dave Ricks, the CEO of Lilly, posted on X just a couple weeks ago, "AI is going to help us conquer disease, but this is going to take time, effort, and lots and lots of data that doesn't exist yet." I would add that robotic labs will begin to make scaling data more tractable. That is a big deal. Robots, if you do not know it, have been sort of relegated to the basements of biopharma companies. They run high-throughput screens, some diagnostic testing, the diagnostic labs runs on robotics. By and large, robots have not been a major part of the overwhelming laboratory investment at pharma companies, which is really manual labs. So, exciting to hear that from the CEO of Lilly. I think Dave is great.
We just sold a system to Novo, which I will talk about, but Dave should probably come by and visit our site in Boston. Anthropic also, if you can believe it, announced that they had set up a biology lab in San Francisco as part of their AI drug discovery efforts. Super exciting. That is not a robotic lab yet, but I do think if you look at the way that those companies think about the world, it is very natural to go for models that can ultimately run the lab experiments themselves, which would be robotics. Okay. As I mentioned, we have two ways to buy the labs. You can either get your own installed or you can use ours in the cloud.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
